| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Pathology, Medical School, University of Manchester, Manchester, UK
3Correspondence: Department of Pathology, Medical School, University of Manchester, M13 9PT, UK. E-mail: MDDPSSK2{at}FS1.SCG.MAN.AC.UK
Angiogenesis is the propelling force for tumor growth and metastasis, and antiangiogenic therapy represents one of the most promising modalities for cancer treatment. CD105 (endoglin) is a proliferation-associated and hypoxia-inducible protein abundantly expressed in angiogenic endothelial cells (EC). It is a receptor for transforming growth factor (TGF) -ß1 and -ß3 and modulates TGF-ß signaling by interacting with TGF-ß receptors I and/or II. Immunohistochemistry studies have revealed that CD105 is strongly expressed in blood vessels of tumor tissues. Intratumoral microvessel density (MVD) determined using antibodies to CD105 has been found to be an independent prognostic indicator, wherein increased MVD correlates with shorter survival. CD105 is able to be shed into the circulation, with elevated levels detected in patients with various types of cancer and positively correlated with tumor metastasis. Tangible evidence of its proangiogenic role comes from knockout studies in which CD105 null mice die in utero as a result of impaired angiogenesis in the yolk sac and heart defects. The potential usefulness of CD105 for tumor imaging has been evaluated in tumor-bearing mice and dogs that have shown the rapid accumulation of radiolabeled anti-CD105 monoclonal antibody in the tumors with a high tumor-to-background ratio. The anti-CD105 antibody conjugated with immunotoxins and immunoradioisotopes efficiently suppressed/abrogated tumor growth in murine models bearing breast and colon carcinoma without any significant systemic side effects. Immunoscintigraphy in patients with renal cell carcinomas has shown specific localization of 99Tcm-labeled CD105 mab in tumor endothelial cells. Thus, CD105 is a promising vascular target that can be used for tumor imaging, prognosis, and bears therapeutic potential in patients with solid tumors and other angiogenic diseases.—Duff, S. E., Li, C., Garland, J. M., Kumar, S. CD105 is important for angiogenesis: evidence and potential applications.
Key Words: HHT1 • tumor prognosis • cancer
This article has been cited by other articles:
|
|
 |
|
  H. Boutrid, M.-E. Jockovich, T. G. Murray, Y. Pina, W. J. Feuer, T. J. Lampidis, and C. M. Cebulla Targeting Hypoxia, a Novel Treatment for Advanced Retinoblastoma Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 2799 - 2805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Dhakal, B. Naume, M. Synnestvedt, E. Borgen, R. Kaaresen, E. Schlichting, G. Wiedswang, A. Bassarova, K.-E. Giercksky, and J. M. Nesland Vascularization in Primary Breast Carcinomas: Its Prognostic Significance and Relationship with Tumor Cell Dissemination Clin. Cancer Res., April 15, 2008; 14(8): 2341 - 2350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Van Buren II, A. D. Yang, N. A. Dallas, M. J. Gray, S. J. Lim, L. Xia, F. Fan, R. Somcio, Y. Wu, D. J. Hicklin, et al. Effect of Molecular Therapeutics on Liver Regeneration in a Murine Model J. Clin. Oncol., April 10, 2008; 26(11): 1836 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Dallas, S. Samuel, L. Xia, F. Fan, M. J. Gray, S. J. Lim, and L. M. Ellis Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy Clin. Cancer Res., April 1, 2008; 14(7): 1931 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Velasco, P. Alvarez-Munoz, M. Pericacho, P. t. Dijke, C. Bernabeu, J. M. Lopez-Novoa, and A. Rodriguez-Barbero L- and S-endoglin differentially modulate TGF{beta}1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts J. Cell Sci., March 15, 2008; 121(6): 913 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bellone, D. Solerio, L. Chiusa, G. Brondino, A. Carbone, A. Prati, T. Scirelli, M. Camandona, G. Palestro, and M. Dei Poli Transforming Growth Factor-{beta} Binding Receptor Endoglin (CD105) Expression in Esophageal Cancer and in Adjacent Nontumorous Esophagus as Prognostic Predictor of Recurrence Ann. Surg. Oncol., November 1, 2007; 14(11): 3232 - 3242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Perez-Gomez, M. Villa-Morales, J. Santos, J. Fernandez-Piqueras, C. Gamallo, J. Dotor, C. Bernabeu, and M. Quintanilla A Role for Endoglin as a Suppressor of Malignancy during Mouse Skin Carcinogenesis Cancer Res., November 1, 2007; 67(21): 10268 - 10277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Anversa, J. Kajstura, and A. Leri If I Can Stop One Heart From Breaking Circulation, February 20, 2007; 115(7): 829 - 832. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yao, Y. Pan, J. Chen, X. Sun, Y. Qiu, and Y. Ding Endoglin (CD105) Expression in Angiogenesis of Primary Hepatocellular Carcinomas: Analysis using Tissue Microarrays and Comparisons with CD34 and VEGF Ann. Clin. Lab. Sci., January 1, 2007; 37(1): 39 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Korpanty, J. G. Carbon, P. A. Grayburn, J. B. Fleming, and R. A. Brekken Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature Clin. Cancer Res., January 1, 2007; 13(1): 323 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Frydelund-Larsen, M. Penkowa, T. Akerstrom, A. Zankari, S. Nielsen, and B. K. Pedersen Muscle: Exercise induces interleukin-8 receptor (CXCR2) expression in human skeletal muscle Exp Physiol, January 1, 2007; 92(1): 233 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Buehler, M. A.M.J. van Zandvoort, B. J. Stelt, T. M. Hackeng, B. H.G.J. Schrans-Stassen, A. Bennaghmouch, L. Hofstra, J. P.M. Cleutjens, A. Duijvestijn, M. B. Smeets, et al. cNGR: A Novel Homing Sequence for CD13/APN Targeted Molecular Imaging of Murine Cardiac Angiogenesis In Vivo Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2681 - 2687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. W. van Laake, S. van den Driesche, S. Post, A. Feijen, M. A. Jansen, M. H. Driessens, J. J. Mager, R. J. Snijder, C. J. J. Westermann, P. A. Doevendans, et al. Endoglin Has a Crucial Role in Blood Cell-Mediated Vascular Repair Circulation, November 21, 2006; 114(21): 2288 - 2297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Guo, H. Li, X. Li, X. Yu, H. Wang, P. Tang, and N. Mao In Vitro Characteristics and In Vivo Immunosuppressive Activity of Compact Bone-Derived Murine Mesenchymal Progenitor Cells Stem Cells, April 1, 2006; 24(4): 992 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Smirnov, B. W. Foulk, G. V. Doyle, M. C. Connelly, L. W.M.M. Terstappen, and S. M. O'Hara Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Res., March 15, 2006; 66(6): 2918 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jerkic, A. Rodriguez-Barbero, M. Prieto, M. Toporsian, M. Pericacho, J. V. Rivas-Elena, J. Obreo, A. Wang, F. Perez-Barriocanal, M. Arevalo, et al. Reduced angiogenic responses in adult endoglin heterozygous mice Cardiovasc Res, March 1, 2006; 69(4): 845 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bertolino, M. Deckers, F. Lebrin, and P. ten Dijke Transforming Growth Factor-{beta} Signal Transduction in Angiogenesis and Vascular Disorders Chest, December 1, 2005; 128(6_suppl): 585S - 590S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bertolino, M. Deckers, F. Lebrin, and P. ten Dijke Transforming Growth Factor-{beta} Signal Transduction in Angiogenesis and Vascular Disorders Chest, December 1, 2005; 128(6_suppl): 585S - 590S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Charalambous, L. B. Pen, Y. S. Su, J. Milan, T. C. Chen, and F. M. Hofman Interleukin-8 Differentially Regulates Migration of Tumor-Associated and Normal Human Brain Endothelial Cells Cancer Res., November 15, 2005; 65(22): 10347 - 10354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fernandez-L, F. Sanz-Rodriguez, R. Zarrabeitia, A. Perez-Molino, R. P. Hebbel, J. Nguyen, C. Bernabeu, and L.-M. Botella Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions Cardiovasc Res, November 1, 2005; 68(2): 235 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A C Browning, T Gray, and W M Amoaku Isolation, culture, and characterisation of human macular inner choroidal microvascular endothelial cells Br. J. Ophthalmol., October 1, 2005; 89(10): 1343 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Suzuki, G.-i. Kusakai, Y. Shimojo, J. Chen, T. Ogura, M. Kobayashi, and H. Esumi Involvement of Transforming Growth Factor-{beta}1 Signaling in Hypoxia-induced Tolerance to Glucose Starvation J. Biol. Chem., September 9, 2005; 280(36): 31557 - 31563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pece-Barbara, S. Vera, K. Kathirkamathamby, S. Liebner, G. M. Di Guglielmo, E. Dejana, J. L. Wrana, and M. Letarte Endoglin Null Endothelial Cells Proliferate Faster and Are More Responsive to Transforming Growth Factor {beta}1 with Higher Affinity Receptors and an Activated Alk1 Pathway J. Biol. Chem., July 29, 2005; 280(30): 27800 - 27808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Smith, R. E. Kontermann, J. Embleton, and S. Kumar Antibody phage display technologies with special reference to angiogenesis FASEB J, March 1, 2005; 19(3): 331 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tang, B. Low, S. A. Rutherford, and Q. Hao Thrombin induces endocytosis of endoglin and type-II TGF-{beta} receptor and down-regulation of TGF-{beta} signaling in endothelial cells Blood, March 1, 2005; 105(5): 1977 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lebrin, M. Deckers, P. Bertolino, and P. ten Dijke TGF-{beta} receptor function in the endothelium Cardiovasc Res, February 15, 2005; 65(3): 599 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Miller, H. H. Pien, D. Sahani, A. G. Sorensen, and J. H. Thrall Imaging Angiogenesis: Applications and Potential for Drug Development J Natl Cancer Inst, February 2, 2005; 97(3): 172 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chen, J. L. Mehta, D. Li, L. Joseph, and J. Joseph Transforming Growth Factor {beta} Receptor Endoglin Is Expressed in Cardiac Fibroblasts and Modulates Profibrogenic Actions of Angiotensin II Circ. Res., December 10, 2004; 95(12): 1167 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Braam, R. de Roos, A. Dijk, P. Boer, J. A. Post, P. P. C. W. Kemmeren, F. C. P. Holstege, H. A. R. Bluysen, and H. A. Koomans Nitric oxide donor induces temporal and dose-dependent reduction of gene expression in human endothelial cells Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H1977 - H1986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ishikawa, K. Takenaka, K. Yanagihara, R. Miyahara, Y. Kawano, Y. Otake, S. Hasegawa, H. Wada, and F. Tanaka Matrix Metalloproteinase-2 Status in Stromal Fibroblasts, Not in Tumor Cells, Is a Significant Prognostic Factor in Non-Small-Cell Lung Cancer Clin. Cancer Res., October 1, 2004; 10(19): 6579 - 6585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Davis, K. Inoue, C. P. N. Dinney, D. J. Hicklin, J. L. Abbruzzese, and D. J. McConkey Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts Cancer Res., July 1, 2004; 64(13): 4601 - 4610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Murillo, A. Arina, I. Tirapu, C. Alfaro, G. Mazzolini, B. Palencia, A. L.-D. De Cerio, J. Prieto, M. Bendandi, and I. Melero Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies Clin. Cancer Res., November 15, 2003; 9(15): 5454 - 5464. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
